1. Catalog
  2. 2025 IASLC CT Screening Symposium
2025 IASLC CT Screening Symposium
Course | English | 2025 | 10-15 min sessions, 4.5 total hours
Create Account
Availability
On-Demand
6 Courses
Cost
Regular Member: $20.00
Member - Other: $10.00
Non-Member: $40.00
Member - Developing Country: $10.00
Non-Member - Developing Country: $20.00
Free: $0.00
Credit Offered
No Credit Offered

This online course is adapted from the CT Screening Symposium featured at the 2025 World Conference on Lung Cancer, September 6, 2025.

The course focuses on advancing lung cancer screening and early detection efforts worldwide, including: best practices; real-world insights on overcoming implementation barriers in diverse settings; downstream effects of lung cancer screening programs; and emerging early detection methods. Learn about actionable strategies, tools, and knowledge to enhance or establish effective lung cancer screening programs in your own setting.

Workshop Sessions:

  • Topic 1: Designing an Optimal Lung Cancer Screening Program
  • Topic 2: Examples of Lung Cancer Screening Programs
  • Topic 3: Downstream Effects of Screening Implementation
  • Topic 4: Alternative Methods for Early Detection of Lung Cancer
Brought to you by the IASLC Screening and Early Detection Committee
Live Activity Date: September 6, 2025
Enduring Activity Launch Date: November 10, 2025
Enduring Activity Expiration Date: November 10, 2026
Radiologists, oncologists, pulmonologists, thoracic surgeons, radiologic technologists, researchers in the field of lung cancer, healthcare administrators, healthcare policy makers, and industry representatives involved in CT imaging and lung cancer diagnostics.
Upon completion of this activity, the participants should be able to:
  • Outline the key components and evidence-based strategies involved in designing an effective, patient-centered lung cancer screening and early detection program.
  • Evaluate real-world examples of lung cancer screening programs to recognize successful models and common barriers across diverse settings.
  • Analyze the downstream clinical and logistical impacts of lung cancer screening implementation on healthcare systems.
  • Illustrate emerging alternative methods for early detection of lung cancer.
Chairs: 
  • Rudolf M. Huber, MD, PhD, Ludwig-Maximilians-University of Munich (LMU), Munich, Germany
  • Catherine Jones, MD, Professor, I-MED Radiology, University of Sydney, Australia
  • Antoni Rosell, MD, PhD, Pulmonology, Hospital Germans Trias, Barcalona, Spain
  • Betty Tong, MD, MHS, Associate Professor of Surgery, Duke University Medical Center, Durham, NC, USA
  • Milena Cavic, PhD, Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Faculty: 
  • Sally Ayesa, MBBS, MSc, Radiologist, University Of Sydney, West Pennant Hills, Australia
  • Claudia Henschke, MD, PhD, Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Long Jiang, MD, PhD, Thoracic Surgeon, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Anna Kerpel-Fronius, MD, National Koranyi Institute of Pulmonology, Budapest, Hungary
  • Ella Kazerooni, MD, MS, Radiology, University of Michigan, Ann Arbor, MI, USA
  • Yeol Kim, MD, PhD, Professor, Department of Public Health, National Cancer Center, Korea, Republic of Korea
  • Stephen Lam, MD, FRCPC, Integrative Oncology, BC Cancer & the University of British Columbia, Vancouver, BC, Canada
  • Stephanie Land, PhD, Tobacco Control Research Branch, National Cancer Institute, Bethesda, MD, USA
  • Nestory Masalu, MD, MMED, Medical Oncologist, Bugando Medical Center, Mwanza, Tanzania, United Republic of Tanzania, Africa
  • Helmut Prosch, MD, Associate Professor, Department of Biomedical Imaging and Image-guided Therapy, Medical University Of Vienna, Vienna, Austria 
  • Nicole Rankin, BA, MSc PhD, Evaluation and Implementation Science Unit, Centre for Health Policy, University of Melbourne, Melbourne, Australia
  • Robert Rintoul, MBBCh, PhD, Professor of Thoracic Oncology, University of Cambridge, UK
  • Hilary Robbins, PhD, Epidemiology, International Agency for Research on Cancer, World Health Organization, Lyon, France
  • Kim L. Sandler, MD, Professor, Radiology and Radiology Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
  • Ricardo Santos, MD, PhD, Thoracic Surgeon, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
  • Suresh Senan, MD, Professor, Radiation Oncology, Amsterdam University Medical Centers, Netherlands
  • Miranda Siemienowicz, MBBS, Thoracic Radiologist, Northern Imaging Victoria, Melbourne, Australia
  • Michael Stenger, MD, PhD, Odense University Hospital, Odense, Denmark
  • Lucia Viola, MD, Interventional Pulmonologist, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center, Bogota, Columbia
  • Chi-Fu Jeffrey Yang, MD, Surgeon, Massachusetts General Hospital, Winchester, MA, USA
The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose: 

Full Legal Name Commercial Interest Role Level of Participation in the Activity
Rudolf Huber 1. AstraZeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck Germany, Lilly, Novocure, Pfizer, Roche, Sanofi, Takeda, Tesaro: acive 1. Advisor 1. Chair
2. Speaker
Anna Kerpel-Fronius 1. Boehringer Ingelheim, Roche 1. Speaker Bureau 1. Speaker
Shun Lu 1. AstraZeneca, Hutchison ，BMS, Heng Rui, Beigene and Hansoh 1. Research (Funding is Paid to Institution) 1. Speaker
Helmut Prosch 1. Boehringer Ingelheim, Astra Zeneca, Siemens
2. Boehringer Ingelheim, MSD, Astra Zeneca, Daiichi Sankyo, Janssen		 1. Research (Funding is Paid to Institution)
2. Consultant		 1. Speaker
Robert Rintoul 1. Owlstone Medical
2. Owlstone Medical		 1. Research (Funding is Paid to Institution)
2. Advisor		 1. Speaker
Antoni Rosell 1. Bess
2. Intuitive Surgival		 1. Funding (Paid as PI)
2. Consultant		 1. Chair
2. Speaker
Kim Sandler 1. RevealDX
2. RevealDX		 1. Advisor
2. Stock Options		 1. Speaker
Suresh Senan 1. AstraZeneca, Lilly, Varian Medical Systems
2. MSD		 1. Research (Funding is Paid to Institution)
2. Advisor		 1. Speaker
Miranda Siemienowicz 1. Boehringer Ingelheim 1. Speaker Bureau 1. Speaker
Chi-Fu Yang 1. AstraZeneca 1. Research (Funding is Paid to Institution) 1. Speaker


"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Study of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationships to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians
The International Association for the Study of Lung Cancer designates the live and enduring activity for a maximum of 4.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Associates
The National Commission on Certification of Physician Associates (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

Successful Completion
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 4.5 MOC point in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program; and
  • 4.5 MOC point (Self Assessment) in the American Board of Thoracic Surgery (ABTS) Maintenance of Certification (MOC) program

It is the CME Activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation. 

Countries that accept ACCME-accredited continuing medical education (CME):

The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians. 

Antigua & Barbuda
Regulator: Antigua & Barbuda Medical Council

Austria
Regulator: Austrian Academy of Physicians on behalf of the Austrian Medical Chamber

Bahamas
Regulator: Bahamas Medical Council

Belgium
Regulator: Group of Belgian Professional Unions of Specialist Doctors

Bhutan
Regulator: Medical and Health Professional Council, Royal Government of Bhutan

Canada
Regulator: Royal College of Physicians and Surgeons of Canada Maintenance of Certification Program

Croatia
Regulator: Croatian Medical Chamber

Gambia, The
Regulator: The Medical and Dental Council of the Gambia

Germany
Regulator: State Chambers of Physicians in the 16 federal states (only in-person, live events)

India, State of Punjab
Regulator: Punjab Medical Council

Israel
Regulator: Scientific Council, Israeli Medical Association

Jamaica
Regulator: Medical Council of Jamaica

Kuwait
Regulator: Professional Licensing - Ministry of Health

Malawi
Regulator: Medical Council of Malawi

Netherlands, The
Regulator: Royal Dutch Society of the Promotion of Medicine

Oman
Regulator: Oman Medical Specialty Board

Qatar
Regulator: Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health

Rwanda
Regulator: Rwanda Medical & Dental Council

Saudi Arabia
Regulator: Saudi Commission for Health Specialties

Singapore
Regulator: Singapore Medical Council

South Africa
Regulator: Health Professions Council of South Africa

Spain
Regulator: Spanish Medical Professional Accreditation Council for CPD/CME

Sri Lanka
Regulator: Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health

Sweden
Regulator: Swedish Medical Association

Trinidad & Tobago
Regulator: The Trinidad and Tobago Medical Association

Turkey
Regulator: Turkish Medical Association CME-CPD Accreditation Council

United Arab Emirates, Abu Dhabi
Regulator: Department of Health

United Arab Emirates, Dubai
Regulator: Dubai Health Authority
The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There is a fee for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Live Activity Credit

To successfully earn credit, participants must complete the activity during the valid credit period that is notes on the title page. Follow these steps to earn CME/CE Credit*

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Participate in the activity.
  3. Complete the activity evaluation to provide feedback for future programs and receive credit.

Enduring Activity Credit

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must complete the evaluation and post-survey. Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out, if applicable.
  3. Complete the activity evaluation to provide feedback for future programming and receive credit.
  4. Complete the post-survey within the required time period.

You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.

If you need any assistance with this activity, please email: education@iaslc.org.
Powered By